2020
Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteria
2019
Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.
Shaikh F, Stark D, Dang H, Xia C, Krailo M, Stenning S, Pashankar F, Rodriguez-Galindo C, Olson T, Hale J, Depani S, Stoneham S, Nicholson J, Murray M, Amatruda J, Billmire D, Fonseca A, Frazier A. Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Journal Of Clinical Oncology 2019, 37: 10022-10022. DOI: 10.1200/jco.2019.37.15_suppl.10022.Peer-Reviewed Original ResearchMalignant germ cell tumorsExtracranial malignant germ cell tumorsEvent-free survivalGerm cell tumorsYoung adultsAdolescent patientsCell tumorsCox proportional hazards analysisIndividual patient databaseCox multivariable analysisPlatinum-based chemotherapyProportional hazards analysisYoung adult patientsPediatric cooperative groupsAdult patientsClinical characteristicsSame regimensMale patientsMultivariable analysisInclusion criteriaPatientsPatient databaseAge groupsAdult groupAdolescent malesCarcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study.
Venkatramani R, Piao J, Krailo M, Rodriguez-Galindo C, Pashankar F. Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study. Journal Of Clinical Oncology 2019, 37: e21505-e21505. DOI: 10.1200/jco.2019.37.15_suppl.e21505.Peer-Reviewed Original ResearchYoung adultsDistant metastasisThyroid cancerChildren's Oncology Group institutionsPercent of patientsEnrollment of patientsRenal cell carcinomaBiology of carcinomaFemale predominanceLymph nodesMedian ageCell carcinomaColorectal cancerCancer patientsMetastasis statusAdrenocortical cancerEpidemiologic informationNasopharyngeal carcinomaWhite raceOutcome studiesPatientsCarcinomaTissue submissionEligibility screeningAge groups
2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatin